Hybridoma Screening

More Diverse Epitopes, More Shots at Success

Comprehensive Hybridoma Workflows for Better Biotherapeutics

Twist’s comprehensive hybridoma workflow includes discovery services for monoclonal antibody production, encompassing antigen production, antibody sequencing, and production. With access to humanized or our proprietary DiversimAb™ mouse platforms, along with cutting-edge hybridoma or Beacon B-cell screening and characterization technologies, our team can create adaptable workflows customized to specific applications such as therapeutic or reagent antibodies.

Boost your Antibody Discovery Efforts

Comprehensive Antibody Discovery

We offer services across all phases of development, addressing key challenges across the preclinical continuum. In the early discovery phase,Twist’s capabilities in protein/peptide synthesis and transient cell line generation ensure a reliable supply of high-quality immunization and screening materials for novel targets.

In late discovery, Twist uses NGS coupled with detailed data to select a
diverse set of developable clones for delivery.

Broad Immunization Expertise

We provide various immunization capabilities, including proprietary adjuvants, peptide/protein-based, subtractive cell-based, DNA-based, VLP-based, and tolerance-breaking immunizations. The hyperimmune response of the DiversimAb™ mouse can produce appropriate titers in as little as three weeks, facilitating rapid antibody discovery.

A Robust Portfolio of Discovery Platforms

We leverage several high- throughput platforms for antibody screening and characterization. These platforms include TECAN systems for high-throughput ELISA, iQue Flow Cytometry for high-throughput cell screening, and Carterra SPR and Octet for antibody kinetics analysis.